SCHEMBL7705459

SCHEMBL7705459

CC(Cc1nc(-c2ccccc2)cs1)c1c(Cl)cc(N)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.48
TAAR1 Q96RJ0 1/20 0.47
ALDH1A1 P00352 6/20 0.45
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
MAPT P10636 4/20 0.45
LMNA P02545 3/20 0.45
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP3A4 P08684 1/20 0.42
CD74 P04233 1/20 0.41
MIF P14174 1/20 0.41
HTR3A P46098 1/20 0.40
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7888535 0.81 MEN1 (0.50) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL7705461 0.79 ALDH1A1 (0.43) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL6455740 0.69 ALDH1A1 (0.46) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL6695943 0.69 LOXL2 (0.60) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL5566029 0.68 LOXL2 (0.64) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL2226853 0.68 LOXL2 (0.74) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL1755714 0.68 LOXL2 (0.64) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL13394621 0.68 LOXL2 (0.64) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL12890735 0.67 LOXL2 (0.54) LOXL2TAAR1ALDH1A1MEN1KMT2A
SCHEMBL13017084 0.66 CYP19A1 (0.49) ALDH1A1KMT2AMAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST LOXL2 473/4885TAAR1 961/4885ALDH1A1 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.